Asia-Pacific Persistent Corneal Epithelial Defects Treatment Market - Industry Trends and Forecast to 2027
Asia-Pacific persistent corneal epithelial defects treatment market By Clinical Causes (Inflammatory Disease, Neurotrophic Keratitis (NK), Epithelial/Limbal Stem Cell Deficiency, Others), Type (Devices, Medication), End User (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Vietnam, Philippines, Rest of Asia-Pacific).
A persistent corneal epithelial defect is a multifactorial condition of the cornea that results from the failure of mechanism of the corneal epithelialization which leads to the disruption in the corneal surface and exposed the eyes vulnerable to the herpetic infections, stromal ulceration and scarring. These defects may persist for several days or even months and it is generally characterized by decreased corneal sensitivity and poor corneal healing. It is manifested by many chronic conditions of the eyes such as limbal cell deficiency, ocular inflammatory disorders, neurotrophic keratitis, herpes simplex and many others.
In healthy eyes, corneal epithelialization plays a crucial role in wound healing and corneal metabolism and thus maintains the cornea’s functionality and integrity. Injury to the corneal surface requires complex corneal epithelialization procedure which involves limbal stem cells acting as, proliferation, cell differentiation and regenerating of the extracellular matrix.
Asia-Pacific persistent corneal epithelial defects treatment market is categorized into five notable segments which are based on the basis of clinical causes, type, end user and distribution channel.
• On the basis of clinical causes, the market is segmented into epithelial/limbal stem cell deficiency, inflammatory disease, neurotrophic keratitis (NK) and others
• On the basis of type, the market is segmented into devices and medication.
• On the basis of end user, the market is segmented into hospitals, homecare, specialty clinics and others.
• On the basis of distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies.
The key market players for Asia-Pacific persistent corneal epithelial defects treatment market are listed below:
• Dompé Farmaceutici S.p.A
• Novartis AG
• Next Biosciences
• Katena Products. Inc.
• Johnson & Johnson Services, Inc.
• Hunt Valley PharmaLAB
• Laboratoires THEA S.A.S
• Skye Biologics Inc.
• I-MED Pharma inc.
• Almirall, S.A
• Ocular Science, Inc.
• Kala Pharmaceuticals
• Bausch Health
• Integra LifeSciences Corporation
• BioTissue (A Subsidiary of TissueTech, Inc.)
The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook